Brief: Larimar Therapeutics Reports Q3 2022 Results

Larimar Therapeutics

10/11/2022 12:40

Nov 10 (Reuters) - Larimar Therapeutics Inc  LRMR.O :
    * LARIMAR THERAPEUTICS REPORTS THIRD QUARTER 2022 OPERATING
AND
FINANCIAL RESULTS
    * LARIMAR THERAPEUTICS - EXPECTS TO PROVIDE AN UPDATE ON
PHASE 2
TRIAL IN Q2 2023 AND ANTICIPATES REPORTING TOP-LINE DATA FROM
BOTH COHORTS IN 2H 2023
    * CASH OF $124.7 MILLION AT SEPTEMBER 30, 2022 PROVIDES
PROJECTED
CASH RUNWAY INTO 2H 2024
    * QTRLY LOSS PER SHARE $0.37
    * Q3 EARNINGS PER SHARE VIEW $-0.42 -- REFINITIV IBES DATA

Source text for Eikon:  ID:nGNXf6v1V 
Further company coverage:  LRMR.O 
 ((Reuters.Briefs@thomsonreuters.com;))